MEDI4736 combinations in metastatic renal cell carcinoma

Trial Profile

MEDI4736 combinations in metastatic renal cell carcinoma

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Durvalumab (Primary) ; Savolitinib; Tremelimumab
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CALYPSO
  • Most Recent Events

    • 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient has been dosed in phase 1b part during Q2 16 and estimated completion date of the trial is Q4 2019.
    • 23 Jun 2016 New trial record
    • 21 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top